Clinical trials
Breast Cancer Patients clinical trials
Below are recruiting breast cancer patients clinical trials, each written for real people, not researchers. We’re tracking 2,247 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06666270RecruitingPhase 1
SYN818 for advanced solid tumors with DNA repair defects
This trial tests a new drug called SYN818 for people with advanced breast, ovarian, prostate, or other solid tumors that have stopped responding to standard treatments. It is designed for patients whose tumors have a specific DNA repair problem (BRCA mutation or other HR pathway deficiency).
Zhengzhou, HenanAges 18 years+ - NCT07016399RecruitingPhase 2
Darolutamide before surgery for AR-positive triple-negative breast cancer
This trial tests a drug called darolutamide, alone or with standard chemotherapy, before surgery for a type of breast cancer that is triple-negative but has a high level of the androgen receptor (AR). It is for people with stage II or IIIA breast cancer that can be removed surgically.
Nashville, TennesseeAges 18 years+ - NCT07252986Recruiting
AI study of breast cancer that has spread
This study uses artificial intelligence to analyze tissue samples from breast cancer that has spread to distant organs, like the liver or lungs. The goal is to develop a tool that predicts how breast cancer might spread, helping doctors personalize treatment.
Hangzhou, ZhejiangAges Any age - NCT07533123RecruitingPhase 3
New drug JSKN016 for triple-negative breast cancer after chemotherapy
This study tests a new drug called JSKN016 against standard chemotherapy options for triple-negative breast cancer that has stopped responding to previous treatments. The trial aims to find out if JSKN016 works better or offers other benefits for patients like you.
Guangzhou, GuangdongAges 18–75 - NCT07601178RecruitingPhase 2
Immunotherapy and targeted drugs for advanced triple-negative breast cancer
This trial tests a combination of four drugs—two immunotherapies (QL1706), an anti-angiogenic agent (anlotinib), and chemotherapy (nab-paclitaxel)—as a first-line treatment for advanced triple-negative breast cancer. The goal is to see if this combination slows or stops cancer growth better than standard treatment alone.
Nanjing, JiangsuAges 18–75 - NCT06414733RecruitingPhase 1
Vaccine for advanced breast or esophageal cancer
This trial tests a vaccine that targets HER2 protein on cancer cells. It is for people with advanced breast or esophageal cancer whose tumors have certain markers. The vaccine may help your immune system fight the cancer.
Indianpolis, IndianaAges 18 years+ - NCT04893109RecruitingPhase 2
Study compares two HER2 breast cancer treatments after surgery
This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.
San Francisco, CaliforniaAges 18 years+ - NCT07531693Recruiting
Improving Outcomes in Early Hormone-Positive Breast Cancer
This study follows women taking abemaciclib (a targeted cancer drug) for early-stage hormone-receptor-positive breast cancer to understand how the treatment affects their quality of life and health outcomes. The goal is to improve care for people in this situation.
Erlangen, BavariaAges 18 years+ - NCT04075305Recruiting
Study measuring radiation treatment outcomes with an MR-Linac
This study follows what happens when radiation treatment is guided using an MR-Linac (a special machine that combines MRI imaging with radiation). It may help improve how radiation therapy is planned and assessed, especially for people who can safely have MRI scans.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05918328RecruitingPhase 2
Testing two medicines before surgery for HER2-positive breast cancer
This Phase 2 trial compares nab-PH plus pyrrolitinib versus TCbHP as treatment given before breast surgery. It aims to see which option works better and is safe for people with HER2-positive invasive breast cancer.
Zhengzhou, HenanAges 18–65 - NCT06242470RecruitingPhase 1
Study of MGC026 for advanced solid tumors
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Los Angeles, CaliforniaAges 18 years+ - NCT01174121RecruitingPhase 2
Immunotherapy made from your tumor-fighting immune cells
This trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes, or TILs) for certain metastatic cancers. It’s designed for people whose cancer has not responded to standard treatments and who can safely provide a small tumor sample for cell-making.
Bethesda, MarylandAges 18–72 - NCT02610439Recruiting
Genetic testing to find causes of paclitaxel nerve damage
This study uses genetic tests on blood DNA to look for differences that may explain why some people develop nerve pain (peripheral neuropathy) from paclitaxel used for breast cancer. It compares people who got significant neuropathy during treatment with people who did not get neuropathy after completing paclitaxel.
Boston, MassachusettsAges Any age - NCT07581834RecruitingPhase 2
Dalpiciclib plus hormone therapy for early hormone-positive breast cancer
This study tests whether adding a new drug called dalpiciclib to standard hormone therapy improves outcomes for women with early-stage breast cancer that is hormone-receptor positive. The goal is to see if this combination is more effective and safe than hormone therapy alone.
Fuzhou, FujianAges 18 years+ - NCT06103864RecruitingPhase 3
Study of Dato-DXd with or without durvalumab for advanced triple-negative breast cancer
This trial is testing whether a new drug combination (Dato-DXd with or without durvalumab) works better than standard chemotherapy plus pembrolizumab for people with a certain type of advanced triple-negative breast cancer that has a protein called PD-L1. The study aims to find a more effective treatment option for this specific group.
Daphne, AlabamaAges 18 years+ - NCT07383649RecruitingPhase 2
Anti-CMV therapy for breast cancer with brain metastases
This trial tests a treatment targeting a common virus (CMV) in breast cancer that has spread to the brain. The goal is to see if anti-CMV therapy can shrink or slow these brain tumors.
Houston, TexasAges 18 years+ - NCT05983107RecruitingPhase 2
Chidamide/Everolimus for advanced breast cancer
This trial tests a combination of two drugs, chidamide and everolimus, for people with advanced HR+/HER2- breast cancer. It aims to see if the combination works for tumors with or without a PIK3CA gene mutation. You may be able to join if you've had previous treatment with CDK4/6 inhibitors and up to two prior chemotherapies.
Beijing, Beijing MunicipalityAges 18–75 - NCT07215364Recruiting
Exercise and quality of life in early breast cancer on hormone therapy
This trial tests if a supervised exercise program can improve quality of life for people with early-stage breast cancer who are currently taking hormone therapy (aromatase inhibitors with or without CDK4/6 inhibitors). It aims to see if exercise helps reduce side effects like fatigue and pain.
L'Hospitalet de Llobregat, BarcelonaAges 18 years+ - NCT05307705RecruitingPhase 1
Testing LOXO-783 for PIK3CA-mutated cancers
This trial tests an experimental drug (LOXO-783) for people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The goal is to see if the drug can shrink or slow the growth of the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT06428682RecruitingPhase 4
TXA for Bleeding in Breast Reconstruction with Free Flaps
This trial tests whether a medicine called TXA (tranexamic acid) can help reduce bleeding during breast reconstruction using your own abdominal tissue. It's for women having this surgery at UVA Medical Center.
Charlottesville, VirginiaAges 18 years+ - NCT07354022RecruitingPhase 3
Study of HRS-8080 with dalpiciclib for advanced breast cancer after hormone therapy fails
This trial tests a new combination of drugs (HRS-8080 and dalpiciclib) for women with advanced or metastatic breast cancer that has stopped responding to initial hormone therapy after surgery. It aims to see if this combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT02610426Recruiting
Genetic testing to study who develops heart failure during breast cancer therapy
This study uses DNA genetic testing to find DNA changes that might explain why some people develop heart failure (CHF) after breast cancer treatment with certain medicines. It may help researchers understand risk and improve care for future patients.
Boston, MassachusettsAges Any age - NCT07551050Recruiting
Sacituzumab Govitecan for Advanced HER2-Negative Breast Cancer
This trial studies how well sacituzumab govitecan (a targeted cancer drug) works for metastatic breast cancer that is HER2-negative. The study focuses on real-world patient experiences and quality of life in Chinese patients.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07524114Recruiting
Blood test to find leftover cancer after treatment
This study uses a blood test to look for tiny bits of cancer DNA after you finish treatment. It may help doctors know if cancer is still there and guide next steps.
Toronto, OntarioAges 18 years+
Hear when a new Breast Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer patients?
- Yes. Clin2 currently lists 2,247 recruiting breast cancer patients studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer patients trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer patients trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.